Gastric Cancer
Conditions
Brief summary
Investigator propose the implementation of circulating biomarker monitoring, focusing on molecules related to the progression of gastric atrophy and/or associated with gastric cancer. Monitoring these biomarkers will provide gastroenterologists with timely information on individuals at risk and, if values worsen during follow-up, will alert physicians observing these patients to evaluate them. This monitoring will be offered to individuals who contact the IBO (Immunopatologia e Biomarcatori Oncologici) Unit at CRO (Centro di Riferimento Oncologico) in Aviano requesting an assessment of gastric function through pepsinogen and G17 gastrin level testing. Monitoring these biomarkers will provide a dynamic analysis of patients' gastric status, allowing for timely intervention in case of deviations from normal values. This proactive approach is important for the preventive management of gastric diseases, particularly for the diagnosis and monitoring of gastric atrophy and gastric cancer. The IBO unit of the CRO in Aviano, together with the pathological anatomy and clinical units of gastroenterology, medical oncology, and surgery, will play a role in coordinating and implementing this monitoring program, thus contributing to the promotion of gastric health and the prevention of associated diseases.
Interventions
None listed
Sponsors
Centro di Riferimento Oncologico - Aviano
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Aged over 18; * Ability to understand, accept, and sign the informed consent form for the study; * Ability to understand, accept, and sign the consent form for data processing; * Ability to understand, accept, and sign the consent form for the collection of a serum sample for research purposes; * Patients who are fasting and have requested a pepsinogen test or gastroscopy, or who have gastric cancer prior to treatment; * Subjects who are fasting and have suspected pre-neoplastic/neoplastic gastric lesions or who have requested a pepsinogen test and for whom endoscopic examination data are available.
Exclusion criteria
* Patients under the age of 18 * Pregnant women * Patients with a coexisting or previous diagnosis of another malignant neoplasm in the last 5 years * Patients unable to understand, accept, and sign the consent form for data processing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the association between the levels of selected biomarkers and the diagnosis obtained after endoscopic examination and histological evaluation of the biopsies taken. | 36 months | The mean value of biomarkers level in positive and negative biopsy will be evaluated |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the prognostic potential of baseline levels of the biomarkers analyzed | 36 months | Mean difference of biomarkers between responders and non responders |
| Identify biomarkers with the best relation with more advanced pre-neoplastic conditions and with neoplasia. | 36 months | Mean difference of biomarkers level in subgroups of patients with the condition under investigation |
| Compare the predictive accuracy of risk between the DSCb test and the DSCb test with the addition of the best-performing biomarker | 36 months | Accuracy will be calculated as number of patients correctly classified over the total number of patients. |
| Monitor test values during follow-up in subjects classified as high risk to assess the possible progression of the pre-neoplastic lesion | 36 months | Likelihood ratio of the two tests will be reported |
| Monitor test values during follow-up in subjects with neoplasia to assess the potential of the test in therapeutic response | 36 months | Test will be compared by mean of ROC curve analysis |
Countries
Italy
Contacts
CONTACTValli De Re, PhD
PRINCIPAL_INVESTIGATORValli De Re
Centro di Riferimento Oncologico
Outcome results
None listed